Document is current
Any future updates will be listed below
-
Authors
Baretti, Marina
Kirk, Allison M. https://orcid.org/0000-0002-4286-3678
Ladle, Brian H.
Kamdar, Zeal
Bendinelli, Kayla J. https://orcid.org/0000-0002-4072-9002
Ho, Won Jin https://orcid.org/0000-0003-2644-5086
Adhikari, Samir https://orcid.org/0000-0003-0406-2498
Clark, Nicholas A.
Sundararaman, Balaji https://orcid.org/0000-0001-8559-1660
Wang, Hao https://orcid.org/0000-0001-6489-6940
Kung, Heng-Chung
Hernandez, Jeric
Qi, Hanfei https://orcid.org/0000-0002-0072-5752
Shin, Sarah M. https://orcid.org/0000-0002-7658-5899
Hernandez, Alexei https://orcid.org/0000-0002-6044-2631
Nakazawa, Mari
Schattgen, Stefan A.
Crawford, Jeremy Chase
Furth, Mark
Anders, Robert A.
Thoburn, Chris https://orcid.org/0000-0001-7743-9183
Zaidi, Neeha https://orcid.org/0000-0002-0094-0049
Huff, Amanda L.
Nauroth, Julie
Jaffee, Elizabeth https://orcid.org/0000-0003-3841-6549
Pogorelyy, Mikhail V.
Thomas, Paul G. https://orcid.org/0000-0001-7955-0256
Yarchoan, Mark https://orcid.org/0000-0003-4401-0748
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01-CA265009)
Conquer Cancer Foundation
Bristol-Myers Squibb
Fibrolamellar Cancer Foundation
- License Information
-
More Information
Article History
Received: 19 February 2025
Accepted: 2 September 2025
First Online: 24 November 2025
Competing interests
: Bristol Myers Squibb provided nivolumab and ipilimumab and support for the clinical trial. M.B. reports advisory board from AstraZeneca. A.M.K holds a patent for a previously described fusion-specific TCR in FLC (US patent number 20220251167). W.J.H. reports patent royalties from Rodeo/Amgen, received research funding from Sanofi, NeoTX, Riboscience (to Johns Hopkins), and speaking/travel honoraria from Exelixis and Standard BioTools. S.M.S received travel honoraria from Standard Biotools. J.C.C. reports patents related to TCR amplification, cloning and/or applications thereof and holds a patent for a previously described fusion-specific TCR in FLC (US patent numbers 20220251167, 20220326216, 20220136051). R.A.A. reports consulting arrangment with Bristol Myers Squib, AstraZeneca, Merck SD and Jazz Pharmaceuticals N.Z. reports research support from Bristol Myers Squibb, is a consultant for Genentech and receives other support from Adventris Pharmaceuticals. A.L.H. is a paid consultant of Adventris Pharmaceuticals, Inc. E.J. reports other support from Abmeta and Adventris, personal fees from Dragonfly, Neuvogen, STIMIT Tx, Mestag, Candel therapeutics, HDTbio, and grants from Lustgarten, Genentech, BMS, NeoTx, and Break Through Cancer. E.J. is a founder of and holds equity in Adventris Pharmaceuticals. She also serves as a consultant to the entity. M.V.P. has patents related to TCR amplification, cloning and/or applications thereof (US patent numbers 20250116673, 20250066852). P.G.T. is on the Scientific Advisory Board of Immunoscape and Shennon Bio; has received research support and personal fees from Elevate Bio; and consulted for CellCarta, RAVentures, 10X Genomics, Illumina, Pfizer, Cytoagents, Sanofi, Merck and JNJ. M.Y. receives grant/research support (to Johns Hopkins) from Bristol Myers Squibb, Exelixis, Incyte and Genentech; receives honoraria from Exelixis, AstraZeneca, Lantheus, Genentech and Incyte; is the coinventor of patents related to therapeutic cancer vaccines (managed by Johns Hopkins, US patent number 20230173049); and is a cofounder with equity of Adventris Pharmaceuticals. M.B., A.M.K, J.C.C., M.V.P., P.G.T. and M.Y. are coinventors on a pending patent application for the fusion-specific TCRs described herein. B.H.L., Z.K., K.J.B., S.A., N.A.C, B.S., H.W., H.-C.K., J.H., H. Q., A.H., M.N., S.A.S., M.F., R.A.A., C.T., A.G. and J.N. have no reported disclosures related to the current work.
